

# 16<sup>th</sup> European Diabetes and Endocrinology Congress

## 3<sup>rd</sup> International Conference on Endocrinology and Diabetes

September 28-29, 2022

WEBINAR

Hazem Rayyan, Endocrinol Diabetes Res 2022, Volume 08

### New Glp1a and Diabetes controlle

#### **Hazem Rayyan**

King Salman Military Hospital-Tabuk, Saudi Arabia

The glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide is the most recently approved agent of this drug class, and the only GLP-1RA currently available as both subcutaneous and oral formulation.

While GLP-1RAs effectively improve glycemic control and cause weight loss, potential safety concerns have arisen over the years. For semaglutide, such concerns have been addressed in the extensive phase 3 registration trials including cardiovascular outcome trials for both subcutaneous (SUSTAIN: Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) and oral (PIONEER: Peptide InnOvatioN for the Early diabEtes tReatment) semaglutide and are being studied in further trials and registries, including real world data studies.

In SUSTAIN programme, Semaglutide was associated with consistent reductions in HbA1c and higher proportions of subjects achieving glycaemic targets of  $<7.0\%$  and  $\leq 6.5\%$ , vs comparators.

In SUSTAIN 6, Semaglutide treated patients experienced a significant 26% risk reduction in the primary composite outcome.

Given the beneficial metabolic and cardiovascular actions of semaglutide, and the low risk for severe adverse events, semaglutide has an overall favorable risk/benefit profile for patient with type 2 diabetes.

#### **Biography**

Hazem Rayyan is a consultant endocrinologist in King Salman Military Hospital-Tabuk-KSA. His research interest was in Diabetes, cardiovascular disease and Drug Agency. He won many awards for his research. He is a member for European Board of Endocrinology also Member of AACE, ESE.

---

**Received:** June 17, 2022; **Accepted:** June 19, 2022; **Published:** September 28, 2022

---